Jeffrey P. Mornhinweg

Array ( [id] => 18596050 [patent_doc_number] => 20230270841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => CORONAVIRUS VACCINE [patent_app_type] => utility [patent_app_number] => 17/914174 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126202 [patent_doc_number] => 20210300970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => COVID-19 VACCINE [patent_app_type] => utility [patent_app_number] => 17/211379 [patent_app_country] => US [patent_app_date] => 2021-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17211379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17110163 [patent_doc_number] => 20210290760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => Bacteriophage-Based Vaccines and Engineered Bacteriophage [patent_app_type] => utility [patent_app_number] => 17/205671 [patent_app_country] => US [patent_app_date] => 2021-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17205671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948478 [patent_doc_number] => 20210207169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => VIRAL DELIVERY OF RNA UTILIZING SELF-CLEAVING RIBOZYMES AND CRISPR-BASED APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/201582 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17201582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16930925 [patent_doc_number] => 20210196814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => Recombinant Modified Vaccinia Virus Ankara (MVA) Respiratory Syncytial Virus (RSV) Vaccine [patent_app_type] => utility [patent_app_number] => 17/202230 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26359 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17202230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17266380 [patent_doc_number] => 11191784 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Methods and composition for gene delivery using an engineered viral particle [patent_app_type] => utility [patent_app_number] => 17/198970 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 40 [patent_no_of_words] => 35820 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17198970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17952469 [patent_doc_number] => 11478543 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-10-25 [patent_title] => Coronavirus disease (COVID-19) vaccine [patent_app_type] => utility [patent_app_number] => 17/193890 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 173 [patent_figures_cnt] => 24 [patent_no_of_words] => 27866 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214854 [patent_doc_number] => 20210348191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => Retroviral and Lentiviral Vectors [patent_app_type] => utility [patent_app_number] => 17/192561 [patent_app_country] => US [patent_app_date] => 2021-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17192561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946749 [patent_doc_number] => 20210205440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => STABILIZED PRE-FUSION RSV F PROTEINS [patent_app_type] => utility [patent_app_number] => 17/249372 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8371 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17249372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883818 [patent_doc_number] => 20210170013 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => OIL-BASED ADJUVANTS [patent_app_type] => utility [patent_app_number] => 17/176749 [patent_app_country] => US [patent_app_date] => 2021-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17183898 [patent_doc_number] => 20210330783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/175278 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -84 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050746 [patent_doc_number] => 20210260180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => CORONAVIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/175131 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16900754 [patent_doc_number] => 20210179670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => HIV Vaccine Formulation [patent_app_type] => utility [patent_app_number] => 17/171295 [patent_app_country] => US [patent_app_date] => 2021-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17997850 [patent_doc_number] => 11498944 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Compositions and methods for preventing and treating coronavirus infection--SARS-CoV-2 vaccines [patent_app_type] => utility [patent_app_number] => 17/163357 [patent_app_country] => US [patent_app_date] => 2021-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 233 [patent_figures_cnt] => 301 [patent_no_of_words] => 117592 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17163357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16837845 [patent_doc_number] => 20210145857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer [patent_app_type] => utility [patent_app_number] => 17/159735 [patent_app_country] => US [patent_app_date] => 2021-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18246840 [patent_doc_number] => 11603413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-14 [patent_title] => Anti-TMPRSS2 antibodies and antigen-binding fragments [patent_app_type] => utility [patent_app_number] => 17/153684 [patent_app_country] => US [patent_app_date] => 2021-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 12 [patent_no_of_words] => 26869 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18246840 [patent_doc_number] => 11603413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-14 [patent_title] => Anti-TMPRSS2 antibodies and antigen-binding fragments [patent_app_type] => utility [patent_app_number] => 17/153684 [patent_app_country] => US [patent_app_date] => 2021-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 12 [patent_no_of_words] => 26869 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16992185 [patent_doc_number] => 20210230605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => USE OF MIR-132 AND MIR-212 IN PREPARATION OF DRUG FOR TREATING ADDICTION [patent_app_type] => utility [patent_app_number] => 17/151667 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2904 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17151667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953679 [patent_doc_number] => 20240042006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => ANTIGEN COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIOUS DISEASES [patent_app_type] => utility [patent_app_number] => 17/997703 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15827 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953679 [patent_doc_number] => 20240042006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => ANTIGEN COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIOUS DISEASES [patent_app_type] => utility [patent_app_number] => 17/997703 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15827 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997703 [rel_patent_id] =>[rel_patent_doc_number] =>)